Per-name detailThe 10 companies, in depth
1. ZTS Zoetis Inc.
DEBATED
Drug Manufacturers - General · adj close 77.29 (div-adj)
Quality
92.8% pctile
Market doubt
0.95 / 1.00
News read — a real but unresolved debate — no clear damage yet: Earnings reveal divided business; pipeline growth potential unresolved. No hard negatives detected.. Leaves the opportunity score about unchanged.
Business quality fingerprint
Returns
ROIC21.5% ▲
ROE80.2%
Gross profitability43.1% ▲
Margins
Gross margin70.5% ▲
Operating margin38.0% ▲
FCF margin24.1% (FCF+)
Growth (3-yr)
Revenue CAGR5.4%
EPS CAGR10.3%
Balance sheet
Net debt / EBITDA1.76
Share count (5-yr)-6.9%
Quality score0.81 · 92.8% pctile
What it does
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents.
Doubt & mispricing
The market doubts it (score 0.95): trading cheap versus its own multi-year range; down 50% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -49.6% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
2. ROL Rollins, Inc.
DOUBT = SENTIMENT
Personal Products & Services · adj close 36.36 (div-adj)
Quality
88.0% pctile
Market doubt
0.96 / 1.00
News read — the doubt looks like sentiment, not damage: Generic stock-forecast articles and institutional investment activity; no fundamental catalyst or deterioration signal.. Lifts the opportunity score to 0.87 (from 0.83).
Business quality fingerprint
Returns
ROIC20.9% ▲
ROE38.3%
Gross profitability59.2% ▼
Margins
Gross margin49.4% ▼
Operating margin19.4% ▲
FCF margin17.3% (FCF+)
Growth (3-yr)
Revenue CAGR11.7%
EPS CAGR13.3%
Balance sheet
Net debt / EBITDA1.10
Share count (5-yr)-1.6%
Quality score0.77 · 88.0% pctile
What it does
Rollins, Inc. operates a network of subsidiaries that specialize in delivering pest and wildlife management solutions to a diverse clientele, encompassing both homeowners and commercial enterprises, throughout the United States and globally. For residential properties, the company offers comprehensive pest control, safeguarding homes from prevalent invaders such as rodents, insects, and other nuisance animals. Furthermore, it devises tailored pest management strategies for various business sectors, including healthcare, foodservice, and logistics.
Doubt & mispricing
The market doubts it (score 0.96): trading cheap versus its own multi-year range; down 44% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -43.9% (skim recent headlines + the last earnings call).
Recent news
3. PODD Insulet Corporation
DEBATED
Medical - Devices · adj close 143.05 (div-adj)
Quality
73.2% pctile
Market doubt
1.00 / 1.00
News read — a real but unresolved debate — no clear damage yet: Multiple shareholder class-action lawsuits filed; securities litigation is a hard negative catalyst.. Lifts the opportunity score to 0.81 (from 0.73).
Business quality fingerprint
Returns
ROIC13.6% ▲
ROE16.3%
Gross profitability60.8% ▲
Margins
Gross margin71.6% ▲
Operating margin17.5% ▲
FCF margin13.9% (FCF+)
Growth (3-yr)
Revenue CAGR27.5%
EPS CAGR275.4%
Balance sheet
Net debt / EBITDA0.63
Share count (5-yr)+4.8%
Quality score0.66 · 73.2% pctile
What it does
Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager. The company's products reach customers predominantly through independent distributors and pharmaceutical…
Doubt & mispricing
The market doubts it (score 1.00): trading cheap versus its own multi-year range; down 59% from its 1-year high, below its 200-day line.
Recommended next step
RESEARCH THE CAUSE FIRST
It's both cheap vs its own 5-yr range AND down hard — find out WHY. Read the latest 10-K/10-Q on SEC EDGAR (sec.gov/edgar) and the most recent earnings-call transcript; separate a temporary stumble from a structural problem before treating the discount as opportunity.
Notable: still growing fast (rev CAGR 27.5%) despite the doubt.
Recent news
4. APP AppLovin Corporation
DOUBT = SENTIMENT
Software - Application · adj close 310.54 (div-adj)
Quality
99.2% pctile
Market doubt
0.80 / 1.00
News read — the doubt looks like sentiment, not damage: Analyst price-target cuts and broad selling pressure; no earnings miss, guidance cut, or fundamental deterioration reported.. Lifts the opportunity score to 0.81 (from 0.79).
Business quality fingerprint
Returns
ROIC60.7% ▲
ROE156.2%
Gross profitability66.3% ▲
Margins
Gross margin87.9% ▲
Operating margin75.8% ▲
FCF margin71.9% (FCF+)
Growth (3-yr)
Revenue CAGR24.8%
EPS CAGR n/a
Balance sheet
Net debt / EBITDA0.24
Share count (5-yr)-0.2%
Quality score0.93 · 99.2% pctile
What it does
AppLovin Corporation provides a specialized software platform focused on empowering mobile application developers to enhance the marketing and revenue generation of their products. With operations spanning the United States and international markets, the company assists mobile app developers worldwide. Among its core software offerings is AppDiscovery, a marketing solution that intelligently connects advertiser demand with publisher supply through an auction-based model. Another key product is Adjust, an analytics platform that enables marketers to scale their mobile apps by offering…
Doubt & mispricing
The market doubts it (score 0.80): down 58% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -57.7% (skim recent headlines + the last earnings call).
Notable: still growing fast (rev CAGR 24.8%) despite the doubt.
Recent news
5. LULU Lululemon Athletica Inc.
DEBATED
Apparel - Retail · adj close 118.33 (div-adj)
Quality
87.2% pctile
Market doubt
0.92 / 1.00
News read — a real but unresolved debate — no clear damage yet: Stock down 64% YTD; no hard negatives cited. CEO reset + U.S. market performance are unresolved secular questions.. Lifts the opportunity score to 0.80 (from 0.76).
Business quality fingerprint
Returns
ROIC22.7% ▼
ROE31.8%
Gross profitability74.3% ▲
Margins
Gross margin56.6% ▼
Operating margin19.9% ▼
FCF margin8.3% (FCF+)
Growth (3-yr)
Revenue CAGR11.0%
EPS CAGR25.7%
Balance sheet
Net debt / EBITDA-0.00
Share count (5-yr)-8.6%
Quality score0.76 · 87.2% pctile
What it does
Lululemon Athletica Inc., alongside its subsidiaries, specializes in the design, global distribution, and retail of athletic apparel and accessories for both women and men. Its business operations are structured into two main divisions: company-owned retail establishments and direct-to-consumer sales. The firm's offerings encompass a range of clothing such as pants, shorts, tops, and jackets, all crafted for promoting a healthy lifestyle and facilitating athletic endeavors. These activities span yoga, running, training, and other physically demanding pursuits.
Doubt & mispricing
The market doubts it (score 0.92): trading cheap versus its own multi-year range; down 45% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -45.2% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
6. ISRG Intuitive Surgical, Inc.
DOUBT = SENTIMENT
Medical - Devices · adj close 371.84 (div-adj)
Quality
91.2% pctile
Market doubt
0.86 / 1.00
News read — the doubt looks like sentiment, not damage: 4.89% price drop with analyst bullishness intact; valuation debate, no fundamental deterioration.. Lifts the opportunity score to 0.80 (from 0.78).
Business quality fingerprint
Returns
ROIC13.7% –
ROE16.0%
Gross profitability32.2% ▲
Margins
Gross margin66.0% ▼
Operating margin29.3% ▼
FCF margin24.7% (FCF+)
Growth (3-yr)
Revenue CAGR17.4%
EPS CAGR29.2%
Balance sheet
Net debt / EBITDA-0.77
Share count (5-yr)-0.8%
Quality score0.80 · 91.2% pctile
What it does
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach.
Doubt & mispricing
The market doubts it (score 0.86): trading cheap versus its own multi-year range; down 37% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -37.3% (skim recent headlines + the last earnings call).
Notable: the balance sheet holds net cash, which de-risks the wait.
Recent news
7. IDXX IDEXX Laboratories, Inc.
DOUBT = SENTIMENT
Medical - Diagnostics & Research · adj close 550.01 (div-adj)
Quality
98.2% pctile
Market doubt
0.78 / 1.00
News read — the doubt looks like sentiment, not damage: CFO option exercise, analyst upside calls, expansion commentary. No hard negatives, earnings miss, or guidance cuts.. Lifts the opportunity score to 0.78 (from 0.74).
Business quality fingerprint
Returns
ROIC40.3% ▼
ROE66.0%
Gross profitability79.4% ▲
Margins
Gross margin61.8% ▲
Operating margin31.6% ▲
FCF margin24.5% (FCF+)
Growth (3-yr)
Revenue CAGR8.5%
EPS CAGR17.7%
Balance sheet
Net debt / EBITDA0.61
Share count (5-yr)-6.8%
Quality score0.89 · 98.2% pctile
What it does
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments.
Doubt & mispricing
The market doubts it (score 0.78): trading cheap versus its own multi-year range; down 28% from its 1-year high, below its 200-day line. Early signs of a turn in margins or returns.
Recommended next step
HOLD OFF — CONFIRM THE TURN
The ROIC/margin upturn is only a period or two old. Wait for the next earnings report to confirm it's a trend (not one print), and watch for upward analyst estimate revisions before acting.
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
8. TTD The Trade Desk, Inc.
DOUBT EARNED
Advertising Agencies · adj close 13.25 (div-adj)
Quality
91.4% pctile
Market doubt
1.00 / 1.00
News read — the doubt looks earned: Q1 earnings miss with weak outlook guidance; stock plummeted post-earnings on realized shortfall.. Cuts the opportunity score to 0.78 (from 0.91).
Business quality fingerprint
Returns
ROIC13.4% ▲
ROE17.8%
Gross profitability37.0% ▲
Margins
Gross margin78.6% ▼
Operating margin20.3% ▲
FCF margin27.5% (FCF+)
Growth (3-yr)
Revenue CAGR22.4%
EPS CAGR102.2%
Balance sheet
Net debt / EBITDA-0.29
Share count (5-yr)-3.2%
Quality score0.80 · 91.4% pctile
What it does
The Trade Desk, Inc. is a global technology company that provides a self-service, cloud-based platform. This platform enables advertising buyers to efficiently create, manage, and optimize data-driven digital ad campaigns across diverse formats and channels, including display, video, audio, native, and social media, reaching audiences on computers, mobile devices, and connected TVs. In addition to the platform, the company offers various data and value-added services.
Doubt & mispricing
The market doubts it (score 1.00): trading cheap versus its own multi-year range; down 76% from its 1-year high, below its 200-day line.
Recommended next step
RECONSIDER — DOUBT MAY BE EARNED
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -76.1% (skim recent headlines + the last earnings call).
Recent news points to realized deterioration, not just sentiment — the cheapness may be a value trap. Confirm the cause before acting (base read would say ‘Buy Candidate’).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
9. ADBE Adobe Inc.
DOUBT = SENTIMENT
Software - Application · adj close 273.92 (div-adj)
Quality
97.4% pctile
Market doubt
0.70 / 1.00
News read — the doubt looks like sentiment, not damage: Price pullback and rotation noise; record revenue reported with no fundamental damage or hard negatives.. Lifts the opportunity score to 0.77 (from 0.68).
Business quality fingerprint
Returns
ROIC36.7% ▲
ROE61.3%
Gross profitability71.4% ▲
Margins
Gross margin88.6% –
Operating margin36.6% –
FCF margin41.4% (FCF+)
Growth (3-yr)
Revenue CAGR10.5%
EPS CAGR18.2%
Balance sheet
Net debt / EBITDA0.12
Share count (5-yr)-11.2%
Quality score0.88 · 97.4% pctile
What it does
Adobe Inc. stands as a prominent global software provider, delivering a diverse range of solutions. Its operations are structured into three primary business divisions: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment empowers individuals, teams, and enterprises to generate, disseminate, and amplify various forms of content through its array of products and services, including the cloud-native Document Cloud platform.
Doubt & mispricing
The market doubts it (score 0.70): trading cheap versus its own multi-year range; down 25% from its 1-year high. Early signs of a turn in margins or returns.
Recommended next step
HOLD OFF — CONFIRM THE TURN
The ROIC/margin upturn is only a period or two old. Wait for the next earnings report to confirm it's a trend (not one print), and watch for upward analyst estimate revisions before acting.
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
10. DECK Deckers Outdoor Corporation
DEBATED
Apparel - Footwear & Accessories · adj close 88.74 (div-adj)
Quality
99.6% pctile
Market doubt
0.75 / 1.00
News read — a real but unresolved debate — no clear damage yet: Q2 sales growth slowed; cost pressures cited. Analyst cut price target 8.9% on tariff headwinds.. Leaves the opportunity score about unchanged.
Business quality fingerprint
Returns
ROIC32.4% ▲
ROE41.0%
Gross profitability83.0% ▲
Margins
Gross margin56.1% ▲
Operating margin22.8% ▲
FCF margin20.1% (FCF+)
Growth (3-yr)
Revenue CAGR14.6%
EPS CAGR29.5%
Balance sheet
Net debt / EBITDA-1.09
Share count (5-yr)-12.6%
Quality score0.93 · 99.6% pctile
What it does
Deckers Outdoor Corporation, operating with its subsidiaries, is a global enterprise dedicated to the creation, promotion, and distribution of footwear, apparel, and accessories. Its product lines serve both casual everyday needs and specialized high-performance activities. The company manages a portfolio of prominent brands: Under the UGG label, it offers premium footwear, clothing, and related items. Teva is known for its range of sandals, shoes, and boots.
Doubt & mispricing
The market doubts it (score 0.75): trading cheap versus its own multi-year range; down 28% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -28.4% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news